Microchemical Journal, Journal Year: 2023, Volume and Issue: 197, P. 109765 - 109765
Published: Dec. 3, 2023
Language: Английский
Analytical Chemistry, Journal Year: 2024, Volume and Issue: 96(4), P. 1693 - 1699
Published: Jan. 17, 2024
Major depressive disorder (MDD) is a prevalent brain affecting more than 2% of the world's population. Due to lack well-specific biomarkers, it difficult distinguish MDD from other diseases with similar clinical symptoms (such as Alzheimer's disease and cerebral thrombosis). In this work, we provided strategy address issue by constructing combinatorial biomarker serum glial fibrillary acidic protein (GFAP) neurofilament light chain (NFL). To achieve convenient sensitive detection two proteins, developed an electrochemical immunosandwich sensor using metal-ion-doped carbon dots (Pb-CDs Cu-CDs) probes for signal output. Each probe contains approximately 300 Pb2+ or 200 Cu2+, providing excellent amplification. This method achieved limits 0.3 pg mL–1 GFAP 0.2 NFL, lower most reported limits. Analysis real samples showed that concentration ratio which associated relative degree inflammation neurodegeneration, suitable not only distinguishing healthy individuals but also specifically thrombosis. The good specificity gives GFAP/NFL broad application prospects in screening, diagnosis, treatment MDD.
Language: Английский
Citations
11
Life Sciences, Journal Year: 2024, Volume and Issue: 355, P. 122988 - 122988
Published: Aug. 15, 2024
Language: Английский
Citations
11
The Lancet Psychiatry, Journal Year: 2024, Volume and Issue: 11(7), P. 566 - 572
Published: March 21, 2024
Language: Английский
Citations
10
Clinica Chimica Acta, Journal Year: 2024, Volume and Issue: 558, P. 118670 - 118670
Published: April 4, 2024
Language: Английский
Citations
9
Biosensors and Bioelectronics, Journal Year: 2024, Volume and Issue: 258, P. 116291 - 116291
Published: April 16, 2024
Language: Английский
Citations
9
Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15
Published: June 13, 2024
Major depressive disorder (MDD) is a recurrent episodic mood that represents the third leading cause of disability worldwide. In MDD, several factors can simultaneously contribute to its development, which complicates diagnosis. According practical guidelines, antidepressants are first-line treatment for moderate severe major episodes. Traditional strategies often follow one-size-fits-all approach, resulting in suboptimal outcomes many patients who fail experience response or recovery and develop so-called “therapy-resistant depression”. The high biological clinical inter-variability within lack robust biomarkers hinder finding specific therapeutic targets, contributing failure rates. this frame, precision medicine, paradigm tailors medical interventions individual characteristics, would help allocate most adequate effective each patient while minimizing side effects. particular, multi-omic studies may unveil intricate interplays between genetic predispositions exposure environmental through study epigenomics, transcriptomics, proteomics, metabolomics, gut microbiomics, immunomics. integration flow information into molecular pathways produce better than current psychopharmacological targets singular mainly related monoamine systems, disregarding complex network our organism. concept system biomedicine involves analysis enormous datasets generated with different technologies, creating “patient fingerprint”, defines underlying mechanisms every patient. This review, centered on explores approaches as tools prediction MDD at single-patient level. It investigates how combining existing technologies used diagnostic, stratification, prognostic, treatment-response discovery artificial intelligence improve assessment MDD.
Language: Английский
Citations
9
Analytical Methods, Journal Year: 2023, Volume and Issue: 15(41), P. 5441 - 5458
Published: Jan. 1, 2023
Rapid and precise detection methods for the early-stage of cardiovascular irregularities are crucial to stopping reducing their development.
Language: Английский
Citations
20
Talanta, Journal Year: 2024, Volume and Issue: 281, P. 126852 - 126852
Published: Sept. 17, 2024
Language: Английский
Citations
5
European Journal of Pharmacology, Journal Year: 2023, Volume and Issue: 965, P. 176301 - 176301
Published: Dec. 23, 2023
Language: Английский
Citations
10
Brain Sciences, Journal Year: 2025, Volume and Issue: 15(3), P. 238 - 238
Published: Feb. 24, 2025
Background: Major depressive disorder is a common mental health issue characterized by persistently low mood and high morbidity mortality. The major pathophysiology neuroinflammation, as evidenced elevated cytokine levels. Patients often fail to achieve full remission with the use of currently available antidepressants, prompting search for new treatment options. Schaftoside (SS), flavonoid found in traditional Chinese herbs, has both antioxidant anti-inflammatory properties. However, its antidepressant effects are poorly understood. Methods: Male C57BL/6 mice underwent chronic unpredictable mild stress (CUMS) lipopolysaccharide (LPS) induce depression- anxiety-like behaviors. SS was administered at 40, 80, 160 mg/kg 28 days. effect on depression-like behaviors assessed using behavioral assays, ELISA used measure pro-inflammatory cytokines serum hippocampus. Results: significantly decreased immobility forced swim tail suspension tests, increased sucrose preference test, reduced feeding latency novelty-suppressed test. These findings indicate improved depression showed that lowered interleukin-1 beta (IL-1β), IL-6, tumor necrosis factor-alpha levels hippocampus CUMS mice. Conclusions: Our study indicates anxiolytic effects, possibly through neuroinflammatory processes, making it promising therapeutic candidate depression, thus deserves further investigation into mechanisms clinical efficacy.
Language: Английский
Citations
0